GSK Rides Cold, Flu And Pain OTCs In Q4 While Allergy Carries Sanofi
This article was originally published in The Pink Sheet
Executive Summary
Firm's "power brands" in respiratory and pain areas achieved high single-digit sales growth in the fourth quarter on an “earlier and more severe” cold season that also drove overall consumer health sales in the period up 4.3% to $2.65bn.
You may also be interested in...
Walmsley: GSK Is 'Prepared' And 'Ready' For US Advair Generic Launch
GlaxoSmithKline is poised for a challenging 2018, with an interchangeable Advair generic expected to launch, but GSK believes growth from new products will make up some of the loss. US Advair sales could be slashed to £750m from £1.6bn in 2017.
Pfizer Mum On Consumer Business Plans As Analysts Say Spin-off
Pfizer continues to review options for its consumer business, though analysts say a spin-off makes most sense. During its fourth-quarter earnings call, firm reported the division's US sales slumped 9% but 12% growth in international markets buoyed the worldwide results.
Consumer Business Reliable And Right At Home At GlaxoSmithKline
CEO Walmsley's familiarity with Glaxo's consumer health business was clear in her response to analysts' questions about the firm's future as a three-unit operation. The business marketing brands including Flonase and Excedrin is a more reliable revenue driver than the pharma business, she said.